Turning Point Therapeutics has entered a strategic research and development alliance with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance the evaluation of two of its investigational small molecules for precision cancer treatments.
The focus of this strategic alliance will be on drug candidates, repotrectinib and elzovantinib (TPX-0022).
Go deeper with GlobalData
A next-generation kinase inhibitor, repotrectinib targets the ROS1 and NTRK oncogenic drivers of advanced solid tumours and non-small cell lung cancer.
It is presently being studied in a registrational Phase I/II study, called TRIDENT-1.
A kinase inhibitor, elzovantinib (TPX-0022) targets MET, CSF1R and SRC.
See Also:
Elzovantinib (TPX-0022) is presently being studied in Phase I of SHIELD-1 trial on patients diagnosed with advanced solid tumours and indicating genetic changes in MET.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe alliance will also focus on potential combinations with other agents, including immunotherapies, chemotherapy, as well as other targeted agents.
Turning Point Therapeutics senior vice president and global product development lead Homa Yeganegi said: “This agreement embodies our commitment to further advancing our innovative macrocyclic programs and complementing our development efforts through collaborative alliances with those who share our vision for breakthrough science.
“We look forward to working with MD Anderson to strengthen our scientific and clinical understanding of our multi-targeted compounds in several tumor types with the goal of speeding delivery of new cancer treatments to patients.”
This alliance will see clinical trial infrastructure and expertise of MD Anderson being brought together with differentiated targeted oncology pipeline of Turning Point.
Spanning a period of five years, the alliance agreement covers preclinical and clinical studies to be undertaken collaboratively in several solid tumours, including gastrointestinal malignancies, non-small cell lung cancers, and endocrine cancers.
MD Anderson Thoracic/Head & Neck Medical Oncology chair John V Heymach said: “There is a major unmet need to develop effective next-generation targeted therapies for cancer patients with oncogene-driven solid tumours, particularly those with mutations that render them resistant to our current therapies.
“Our alliance with Turning Point represents an important opportunity to work toward advancing new treatment options for patients using novel inhibitors that target multiple driver mutations with the most characterised resistance patterns in common cancers.”
The studies taken up under the collaboration will be overseen by a joint steering panel.
During the term of the alliance, Turning Point will be responsible for funding, and providing study materials and other ongoing support.
